Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Etanercept (Enbrel®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0210. 2010 Authors' conclusions Etanercept (Enbrel®) is not recommended for use within NHS Wales for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of eight years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. The cost effectiveness data presented was insufficient for AWMSG to recommend the use of etanercept (Enbrel®) in NHS Wales. Indexing Status Subject indexing assigned by CRD MeSH Humans; Immunoglobulin G; Immunosuppressive Agents; Psoriasis; Receptors, Tumor Necrosis Factor Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000395 Date abstract record published 08/08/2012 |